Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center , University Medical Center, shared on LinkedIn:
“T-cell redirecting therapies in lung cancer review by fellow Jiahe Zhao, Ayrton Bangolo, Lili Zhang under the mentorship of Martin Gutierrez, MD at Frontiers-Immunology.
Take: Tarlatamab is the only modality with traditional FDA approval in lung cancer (DeLLphi-304: OS 13.6 vs 8.3 mo).
TIL is the most mature adoptive approach in NSCLC (64.3% ORR with pembro in ICI-naive disease).
CAR-T and TCR-T remain early proof-of-concept global CAR-T ORR still under 10% in lung cancer.
Still a lot of challenges to overcome in cellular therapies in lung cancer.”
Title: T-cell redirecting therapies in lung cancer – a comprehensive analysis of clinical trials
Authors: Jiahe Zhao, Ayrton Bangolo, Lili Zhang, Martin Gutierrez, Miguel Gonzalez-Velez
Read the Full Article
Other articles about Lung Cancer on OncoDaily.